Cargando...
Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies that inhibit specific steps of the mitogen‐activated protein kinase pathway have been shown to provide significant overall treatment benefit in...
Guardado en:
| Publicado en: | Oncologist |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
AlphaMed Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5507648/ https://ncbi.nlm.nih.gov/pubmed/28526719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0456 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|